Phase I/II Trial of Sorafenib and Weekly Bortezomib in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma.
Phase of Trial: Phase I/II
Latest Information Update: 24 Nov 2013
At a glance
- Drugs Bortezomib; Sorafenib
- Indications Multiple myeloma
- Focus Therapeutic Use
- 26 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 May 2011 Planned end date changed from 1 Sep 2010 to 1 Aug 2011 as reported by ClinicalTrials.gov.
- 03 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.